Intro

This chapter explores the management of clozapine for treatment-resistant schizophrenia, highlighting serious side effects such as bowel obstruction and pneumonia. It reviews a 25-year Finnish study that reveals critical long-term risks, urging healthcare professionals to be vigilant beyond the well-known concern of agranulocytosis.